HARP News and Press, Harpoon Therapeutics Inc. From 06/04/21

Gainers: SemiLEDs (LEDS) +66%.Senseonics (SENS) +49%.Windtree Therapeutics (WINT) +38%.MoSys (MOSY) +34%.Ra Medical Systems (RMED) +29%.LightPath Technologies (LPTH) +27%.American Superconductor (AMSC) +26%.Smart Sand (SND) +25%.The9 (NCTY) +24%.Vinco Ventures (BBIG) +22%....

Gainers: Windtree Therapeutics (WINT) +57%, Senseonics (SENS) +38%, Ra Medical Systems (RMED) +22%, Cullinan Oncology (CGEM) +20%, Progenity (PROG) +10%.Losers: Harpoon Therapeutics (HARP) -25%, Purple Biotech (PPBT) -19%, Adamis Pha...

Harpoon Therapeutics shares fall ([[HARP]] -21.6%) after interim data from its ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate cancer ((mCRPC)) failed to impress investors.The ongoing dose escalation Phase 1/2a tr...

The ongoing dose escalation Phase 1/2a trial has enrolled 89 patients with progressive, metastatic castration-resistant prostate cancer in 13 cohorts. Safety data continues to show that HPN424 is generally well tolerated, and cytokine-related adverse events have been transient and...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Iterum jumps even as RBC says sulopenem may not be a “shoo-in”Iterum Therapeutics (ITRM) is extending the post-market gains with a ~18.7% rise in early hours in reaction to the FDA decision not to hold an AdCom meeting for the company’s marketing application for...

SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at ...

Harpoon Therapeutics (HARP): Q1 GAAP EPS of -$1.95 misses by $1.50.Revenue of $9M (+172.7% Y/Y) beats by $2.39M.Press Release For further details see: Harpoon Therapeutics EPS misses by $1.50, beats on revenue

Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader A lan Colowick, M.D., to board of directors Clinical data updates for a ...